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Abstract
Mice infected with relapsing fever (RF) spirochaetes survive recurrent waves of high-level bacteraemia with little, if any, clinical compli-
cations or tissue injury. In the absence of B-cells, peak bacteraemia does not resolve, resulting in multi-organ complications. During peak
bacteraemia, large amounts of interleukin-10 (IL-10) are produced in blood and tissues. In mice unable to clear peak bacteraemia, exog-
enous IL-10 greatly reduced the clinical manifestations, serum levels of CXCL13, cerebral microgliosis, and the pathogen load. In con-
trast, IL-10 deﬁciency in mice unable to clear peak bacteraemia resulted in microvascular complications with distinct severities,
depending on the serotype: serotype 2 (Bt2), which causes peak bacteraemia of c. 108/mL, resulted in rapid death from subarachnoid
and intraparenchymal haemorrhage; in contrast, serotype 1, which causes peak bacteraemia of c. 107/mL, resulted in milder multi-organ
haemorrhage and thrombosis. IL-10 deﬁciency also resulted in multi-organ haemorrhage and thrombosis with infarction in wild-type
mice despite lower peak bacteraemia. Two mechanisms for pathogen control have been identiﬁed: antibody clearance of peak bacter-
aemia, and antibody-independent lowering of bacteraemia via phagocytosis in the spleen. IL-10 plays opposite roles in pathogen control,
depending on the severity of bacteraemia: during persistent high bacteraemia, IL-10 helps to control it by protecting innate immune cells
from apoptosis; in contrast, during transient peak bacteraemia, IL-10 slows down antibody-mediated clearance. A successful outcome
from RF depends on a balanced immune response to clear bacteraemia while avoiding microvascular injury, in which production of
IL-10, in response to the pathogen load, plays a critical role.
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Introduction
Relapsing fever (RF) is a multisystemic spirochaetal infection
caused by a variety of Borrelia species that occurs in two
forms, epidemic and endemic. Epidemic RF is louse-borne
and caused by Borrelia recurrentis, whereas endemic RF is
tick-borne and caused by different Borrelia species in endemic
areas throughout the world [1]. The clinical and pathological
manifestations of RF borreliosis are diverse, depending on
the Borrelia species and the genetic background of the host.
The relapsing course of the disease is caused by antigenic
variation of RF spirochaetes, which results in febrile periods
at times of high bacteraemia, alternating with periods of rela-
tive wellbeing during low bacteraemia. IgM antibodies speciﬁc
for outer membrane lipoproteins are responsible for resolu-
tion of bactaeremic peaks [2–6]. Untreated infection can
result in multisystemic complications, and even death. Our
laboratory studies the immunopathogenesis and tissue tro-
pism of the North American RF spirochaetes Borrelia hermsii
[2] and Borrelia turicatae [7–9] in mice.
Infection
All outbred stocks (Swiss Webster) and inbred strains
(C57BL/6, B10, BALB/c, C3H/HeJ, and SWR) of the mice
that we have tested are susceptible to infection with North
American RF spirochaetes [2,10,11]. The magnitude of peak
bacteraemia varies from 105/mL to 108/mL, with higher
counts usually being observed during the ﬁrst peak and when
higher inocula are used, or in B-cell-deﬁcient mice [2,10].
After inoculation of mice with a single RF spirochaete, peak
bacteraemia usually occurs on day 4, after which clearance
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occurs, and the original inoculum is replaced by a mixed
population that persists for 2–3 days before being replaced
by newer serotypes [2,12]. RF spirochaetes are found free in
the blood and extravascularly in the interstitium of multiple
tissues, including the skin, the joints, the heart, the aorta, the
leptomeninges, the subarachnoid space, the brain paren-
chyma, and the labyrinth [13,14]. Like the causative agent of
Lyme disease, RF spirochaetes show a distinct tropism for
collagenous tissues [13].
An interesting phenomenon in RF is that the brain often
continues to be infected after the blood has ceased to be;
this is referred to as residual brain infection [7]. In our
laboratory, we observed residual brain infection in 20% of
mice examined 1 month after intraperitoneal inoculation
with B. turicatae [10]. Approximately 20% of mice develop
persistent infection in the blood, and this was observed
more frequently in TLR2-deﬁcient mice [10]. Although, in
the majority of cases, residual brain infection is caused by
new serotypes, in at least one case it was caused by the
serotype that was originally inoculated [10]. A study of
residual brain infection due to different Borrelia spp. showed
that it is more prevalent with the African species Borrelia
duttonii [15]. The average pathogen load during residual brain
infection was determined to be c. 2000 spirochaetes per
gram of brain. RF spirochaetes causing residual brain
infection can re-infect the blood if immunosuppression
occurs [15].
Clinical Complications
There is great heterogeneity in the clinical manifestations of
RF in experimental animals, depending on the immune status
of the host and the infecting organism. The severity of clinical
disease is proportional to the pathogen load. Therefore,
animals inoculated with large numbers of organisms tend to fall
ill and even die early on [16]. Inoculation with B. recurrentis in
grivet monkeys (Cercopithecus aethiops) uniformly caused high
fever and resulted in 20% mortality, including two animals
during a severe relapse [17]. Although we never observed
clinical disease in various strains of inbred mice inoculated with
B. turicatae, they did occur in all B-cell-deﬁcient mice that we
tested, independently of their genetic background. They
include purulent eye discharge, rufﬂed skin, tibiotarsal joint
reddening and swelling, and vestibular dysfunction [10].
Clinical complications have also been observed sporadically in
outbred mice. Old World RF spirochaetes appear to be more
pathogenic than New World species; inoculation of BALB/c
mice with Borrelia crocidurae, but not with B. hermsii, resulted in
clinical disease [11,18].
Tissue Tropism
During infection of wild-type mice with B. hermsii, we
noticed, in several cases, the presence of serotypes in the
blood that were not present in the brain [2]. This suggested
that some serotypes of RF spirochaetes are more neuro-
tropic than others. As serotype-speciﬁc antibodies rapidly
clear RF spirochaetes from blood and tissues [2,12,19], we
switched to B-cell-deﬁcient mice to study serotype tropism.
For this, we chose a strain of B. turicatae responsible for an
outbreak of RF in Texas (USA) that resulted in prominent
neurological complications, including meningitis and facial
paralysis. Infection with this strain was well tolerated by
SCID mice, which are B-cell-deﬁcient and T-cell-deﬁcient,
without any mortality for at least 100 days [11]. Seven days
after inoculation, we documented the presence of at least
three serotypes, all of them present in both blood and brain
[11]. Fifty days after inoculation, these three serotypes had
been replaced by two new serotypes, one of which was pre-
dominant and appeared to be well tolerated. However, over
the next 50 days, this serotype was gradually replaced by the
second one, which was more virulent [11]. The two sero-
types, originally named A and B, and since then renamed 1
and 2, have been extensively studied to examine their viru-
lence and tissue tropism. The only discernible difference
between them is the variable major protein that they
express, 23-kDa variable small protein 1 in serotype 1 (Bt1),
and 20-kDa variable small protein 2 in serotype 2 (Bt2)
[20–22]. Although both serotypes have similar abilities to
establish infection with as little as one spirochaete per
mouse and to disseminate to distant tissues, clinical examina-
tions in various B-cell-deﬁcient mice, studied for up to
2 months, have revealed marked differences in their
virulence and tissue tropism [11,14,23–27]. Only Bt2 kills
infant mice. In adult mice, clinical disease manifested in the
ﬁrst week with purulent discharge from the eyes and rufﬂed
skin, and this was followed in the second week by tibiotarsal
joint swelling and redness, and by the third or fourth week
by signs of vestibular dysfunction [11]. The differences in
joint involvement between the two serotypes was most
striking, with tibiotarsal and metatarsal joint reddening and
swelling beginning earlier and becoming more severe with
Bt2 [11]. Bt2 also caused more severe functional impairment
in an equilibrium bar test. In contrast, Bt1 caused more
severe vestibular disease but only after several weeks of
persistent infection [28]. Bt1 also appeared to be more
neurotropic than Bt2 [11]. When brain infection was studied
by culture of whole brain homogenates, Bt1 was found in
the brain much more frequently than Bt2 [11]. Furthermore,
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only Bt1 was apparent according to western blot on brain
cultures from SCID mice that were co-infected with Bt1 and
Bt2 [11]. As Bt2 had no problems infecting the brain after
intracerebral inoculation [11], this suggests that Bt1 is better
than Bt2 at crossing the blood–brain barrier or that the
function of the blood–brain barrier is better preserved
during infection with Bt2. Using immunohistochemistry, we
found ﬁve times as many Bt1 as Bt2 spirochaetes in the
leptomeninges in SCID mice examined 18 days after inocula-
tion [13]. TaqMan RT-PCR showed that the mean number of
spirochaetes per gram of brain RNA 1 month after inocula-
tion was approximately ten-fold higher with Bt1 than with
Bt2 [14]. The pathogen load in the brains of mice co-infected
with Bt1 and Bt2 was intermediate between that of mice
infected with either serotype alone [10], suggesting that
co-infection with Bt2 decreases the entry of Bt1 into the
brain. A comparison of mice co-infected with Bt1 and Bt2
also revealed that the severe vestibular dysfunction caused
by Bt1 was prevented by co-infection with Bt2. In contrast,
the severe arthritis and weight loss caused by infection with
Bt2 alone were not inﬂuenced by co-infection with Bt1 [28].
The high number of spirochaetes found in blood and tissues
of B-cell-deﬁcient mice inoculated with B. turicatae provided an
opportunity to study their dissemination to various tissues
after intraperitoneal inoculation [13]. Whole decalciﬁed heads
were used to study multiple tissues simultaneously without
disrupting important anatomical relationships. Spirochaetes
were observed microscopically as early as 4 days after inocula-
tion [13]. The ﬁrst tissue in which spirochaetes were observed
outside of the vasculature was the dura mater [13]. In the
brain, the localization was primarily leptomeningeal, although,
rarely, spirochaetes were also found in the brain parenchyma
itself. The site of entry into the brain appeared to be the
leptomeningeal microcirculation, where they were observed
attached to, or in the process of crossing, brain–microvascular
endothelial cell junctions [14]. The spirochaetes were not
limited to the central nervous system. They were also
observed in the middle and inner ear, endoneurium and
perineurium of cranial and peripheral nerves, skin, bone
marrow, and heart [13,25]. Clumps of spirochaetes were
observed in the subarachnoid space, inner ear, and skin.
Spirochaetes were also found in the extracellular matrix of
skeletal and cardiac muscle. No spirochaetes were found in
salivary glands or in the choroid plexus or intracellularly
[13,14]. Whereas Bt2 was more abundant in the skin [13], the
heart [25], and the tibiotarsal joints [29], Bt1 was more
abundant in the leptomeninges. In all B-cell-deﬁcient mice that
we have tested, including SCID and RAG1, RAG2 and Igh6 null
mice, the pathogen load in the blood was ﬁve to ten times
higher with Bt2 than with Bt1 [14,23,24,26,30].
We studied the pathogen load during co-infection with
various serotypes indirectly by comparing circulating levels of
the B-cell chemokine CXCL13 in SCID mice persistently
infected with Bt2 alone or in combination with Bt1 [28]. This
approach was valid because the levels of this chemokine cor-
relate very strongly with the pathogen load in Borrelia infec-
tions [23,31]. The results revealed that co-infected mice had
signiﬁcantly higher CXCL13 levels than mice infected with
Bt2 alone; the mean (standard deviation) serum pg/mL
CXCL13 was 72 625 (4750) in co-infected mice, as com-
pared with 42 625 (5406) in mice infected with Bt2 alone
(p <0.001) [28].
Pathology
Examination of the blood during acute RF revealed
increased numbers of neutrophils, lymphocytes, and mono-
cytes, and anaemia [18,32]. However, when mice were inoc-
ulated with very large numbers of spirochaetes, the
opposite was observed: a decline in the number of circulat-
ing leukocytes that was proportional to the increase in bac-
teraemia [16]. Infection with RF spirochaetes also causes
thrombocytopenia [16,18,32], which also correlates with the
magnitude of bacteraemia [33]. Another consistent ﬁnding in
infected mice is marked hepatosplenomegaly [16,18,27,32].
Infection with some RF species can lead to inﬂammation of
the heart with perivascular mononuclear cell inﬁltrates in
the pericardium and myocardium, with interstitial oedema
and necrosis of cardiomyocytes [32,34,35]. Prominent vascu-
lar pathology with high mortality did occur after inoculation
with large numbers of Old World RF spirochaetes [16];
microscopic examination revealed blood vessel ﬁbrin
thrombi in the kidneys, liver, spleen, brain, and lungs, promi-
nent focal areas of endothelial cell swelling, and nuclear pyk-
nosis and karyorrhexis in hepatocytes and Kupffer cells
[16,18].
Another common pathological ﬁnding in mice during the
course of RF is inﬂammation in the brain [7]. Wild-type and
TLR2-deﬁcient C57BL/6 mice inoculated with Bt1 developed
mild leptomeningeal inﬂammation and brain parenchymal
macrophage inﬁltration/microglial activation (upper panels in
Fig. 1), with few, if any, lymphocytes, and absent neutrophils
[10]. Inoculation of BALB/c mice with B. crocidurae resulted in
increased numbers of perivascular macrophages, and micro-
gliosis with small numbers of lymphocytes and granulocytes
in the brain [36]. Mice inoculated with an RF strain from
Spain developed perivascular mononuclear cell inﬁltration of
the leptomeninges, accumulation of activated macrophages
perivascularly, and plexitis [32,37]. Unlike during acute
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infection, no evidence of inﬂammation was found in the
brains of mice experiencing residual brain infection [15].
Studies in B-cell-deﬁcient mice persistently infected with
Bt1 or Bt2 have shown marked differences in their pathoge-
nicity [11,14,23–28]. SCID mice inoculated with Bt1 or Bt2
develop frank arthritis after 2 weeks that is more severe
with Bt2 [11]. Haematoxylin and eosin-stained sections
revealed mixed inﬂammation of the synovial lining of both
joints and tendon sheaths with mononuclear and polymor-
phonuclear cells, and prominent thickening of the synovium
and leukocyte exudate in the joint space. There was also
prominent inﬂammation and tissue injury in the heart.
Cardiac inﬂammation involved both the myocardium and
pericardium, and was characterized by a prominent mononu-
clear leukocytic inﬁltrate between myocardial ﬁbres, with
exudate in the pericardium. Cardiac inﬂammation was more
severe in the atria and around the great vessels in the
mediastinum [11,25], similar to what has been seen in
Lyme borreliosis [38].
The loss of cardiomyocytes, macrophage inﬁltration and
upregulation of interleukin-6 were all more prominent in the
atrium and more severe with Bt2 than with Bt1 [25]. Mor-
phological features of apoptosis, including fragmented nuclei
and condensed chromatin, terminal deoxynucleotidyl trans-
ferase dUTP nick end labelling positivity, and BAX immuno-
staining, were readily apparent in areas of cardiomyocyte
injury. Analysis of caspase activation showed signiﬁcant
upregulation of several caspases, most notably caspase 1
and caspase 11, with strong expression in areas of injury
that co-localized with activated macrophages. Similar cardio-
myocyte apoptosis was observed in RAG1 and Igh6 null
mice, with prominent upregulation of tumour necrosis factor
(TNF) and interleukin-10 (IL-10) of similar degree with Bt1
and Bt2 [23,25].
The severity of inﬂammation in the skin was similar with
either serotype [13]. Signiﬁcant inﬂammation was also found
in the vestibular and auditory labyrinths with either serotype,
which probably explains the prominent vestibular dysfunction
that characterizes this model [28]. Mild inﬂammation was
also found in the leptomeninges, with no obvious difference
between Bt1 and Bt2.
Although haematoxylin and eosin staining in SCID mice did
not reveal any apparent abnormalities in the brain
parenchyma, immunostaining for F4/80, a marker of activated
microglia/macrophages, revealed that infection resulted in
widespread inﬁltration by activated macrophages/microglia
with a 30-fold increase with Bt1, as compared with
uninfected controls [14]. Microgliosis with Bt2 was only
four times greater than that in uninfected controls. The
morphology of F4/80-stained cells was heterogeneous, with
some cells being amoeboid (upper left panel in Fig. 1) and
some ramiﬁed (upper right panel in Fig. 1). Similar ﬁndings
were observed in RAG1 and Igh6 null mice, with
prominent upregulation of TNF and IL-10 by 2 weeks, but
only upregulation of IL-10 remaining after 4 weeks [23].
Fully activated microglia were the main source of IL-10 in
the brain. A comparison of gene expression in Igh6 null
mice persistently infected with Bt1 with uninfected
controls revealed upregulation of many genes known to be
upregulated during microglial activation [23]. The
gene encoding CXCL13 was the most highly upregulated
gene in infected brains, and CXCL13 was also the most
abundant of the chemokines that we measured in the
blood [23]. An analysis of functional categories within the
gene ontology database showed that the majority of
categories with the highest EASE scores referred to
functions of the immune response to pathogens, including
proteins involved in antigen processing and presentation,
chemotaxis, adhesion, and migration, lipopolysaccharide/
FIG. 1. Spectrum of brain pathology in relapsing fever (RF). Infection
with the RF spirochaete Borrelia turicatae can result in prominent
changes in the brain parenchyma that vary from macrophage inﬁltra-
tion/microglial activation (top panels, ·1000 magniﬁcation) of varying
degrees in wild-type and B-cell-deﬁcient mice to severe intracerebral
haemorrhage (left lower panel) with prominent brain microvascular
endothelial cell apoptosis (right lower panel) in RAG2-deﬁcient mice
infected with serotype 2. The upper panels show immunoﬂuores-
cence staining with rat monoclonal antibody anti-mouse F4/80. The
left lower panel shows haematoxylin and eosin staining of the cere-
bellum, and the right lower panel shows terminal deoxynucleotidyl
transferase dUTP nick end labelling staining of the cerebral cortex.
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lipoprotein toll-like receptor ligation and signalling, and
pathogen control and host defence [23]. A surprising
ﬁnding of these studies was the lack of any evidence,
either morphological or according to gene arrays, of brain
injury, despite persistent infection.
Protective Role of IL-10
During the studies on persistent infection in B-cell-deﬁcient
mice, we were intrigued by the observation that, despite the
absence of speciﬁc antibody to clear the infection, many clini-
cal manifestations either resolved completely (purulent eye
discharge) or signiﬁcantly decreased (rufﬂed fur and arthritis)
over days to weeks [11]. Similarly intriguing was the observa-
tion that persistent infection with the more virulent serotype
Bt2 protected mice from the severe and fatal vestibular dys-
function that characterized persisting infection with Bt1 [28].
The ﬁrst clue as to a possible explanation for these observa-
tions came from a study comparing the severity of clinical
disease between RAG1 null mice, which are B-cell-deﬁcient
and T-cell-deﬁcient, and Igh6 null mice, which lack only
B-cells. This study showed that although RAG1 null mice
developed a higher pathogen load, they had much less severe
clinical disease and produced more IL-10 [23,24]. This was
an important observation, in view of the previous report by
Cooper et al. [39] that humans infected with the louse-borne
RF spirochaete B. recurrentis have extraordinarily high levels
of circulating IL-10 at times when they appear to be
relatively well. In fact, IL-10 had the highest levels among all
the cytokines that we measured, with a strong positive
correlation with the pathogen load. The increase in IL-10
levels was associated with a concomitant decrease in
circulating levels of TNF and all other proinﬂammatory
cytokines and many chemokines [24,27]. The upregulation of
IL-10 was found not only in blood, but also in other tissues,
including the heart and the brain [24].
The ﬁrst direct evidence that IL-10 was responsible for
the previously observed amelioration of clinical disease came
from the observation that giving infected Igh6 null mice
exogenous IL-10 reduced bacteraemia, clinical disease, cere-
bral microgliosis, and serum CXCL13 levels [23,24,27]. The
lowering of the pathogen load in Igh6 null mice was opposite
to the ﬁnding in wild-type mice infected with RF [30] or
Lyme disease [40] spirochaetes that IL-10 deﬁciency lowered
the pathogen load via improved speciﬁc-antibody production.
Deﬁnite proof of the fundamental protective role of IL-10 in
RF came from the observation that in Bt2-infected RAG2
null mice, IL-10 deﬁciency resulted in increased bacteraemia
with rapid death due to severe intracerebral haemorrhage
and apoptosis of brain microvascular endothelial cells (lower
panels in Fig. 1) [26,27]. The protective role of IL-10 was
not restricted to RAG2 null mice infected with Bt2, as IL-10
deﬁciency also resulted in multi-organ haemorrhage and
microvascular thrombosis in Bt1-infected RAG2 null mice
[26] and in wild-type mice that had been inoculated with Bt2
[30].
During RF in wild-type mice, serum levels of IL-10
increased but only at times of peak bacteraemia (Fig. 2).
Remarkably, although mice examined during peaks of bacter-
aemia had high serum levels of IL-10, IL-10 was absent on
the day following resolution of peak bacteraemia. This sug-
gests that peak bacteraemia in RF triggers transient produc-
tion of IL-10 in the circulation. A clue to the role of IL-10
production came from the ﬁnding that IL-10-deﬁcient mice
developed microvascular injury and thrombosis with
infarction in the liver, even though their peak bacteraemia,
c. 104/mL [30], was much lower, and the original serotype
was cleared faster (unpublished observation). The lower
peak bacteraemia was probably the result of stronger pro-
duction of serotype-speciﬁc antibodies [30], which was prob-
ably facilitated by strong production of the B-cell chemokine
CXCL13 in the absence of IL-10 (Fig. 3). These results indi-
cate that a fundamental protective mechanism during RF
is the production of IL-10 at times of peak bacteraemia to
prevent vascular injury, which may be fatal. This observation
FIG. 2. Serum levels of interleukin-10 (IL-10) in relapsing fever (RF)
in mice. Groups of four to eight wild-type mice were necropsied at
various times after inoculation of serotype 2 of the RF spirochaete
Borrelia turicatae (Bt2), and the serum levels of IL-10 were measured
by ELISA in comparison with uninfected control mice (phosphate-
buffered saline (PBS)). Infected mice were necropsied during the ﬁrst
peak of bacteraemia (day 4), immediately after resolution of peak
bacteraemia (day 5), or on day 14, when some mice were experienc-
ing another peak of bacteraemia. Note that IL-10 was found in
serum only during peak bacteraemia.
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has important implications for our understanding of RF in
humans.
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